Schedule 13D ownership disclosure

X4 PHARMACEUTICALS INC

Security class unavailable · CUSIP: 98420X103

Event date: 2019-03-13

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
311,493
Percent of class
4.6500%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-19-000210
Form type
SC 13D/A
Filer
ORBIMED ADVISORS LLC
CIK
CIK 1055951
Filed
Mar 19, 2019
Reporting period
Mar 13, 2019
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub